- $1.39bn
- $1.48bn
- $53.04m
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
Brief: Anaptys Announces Second Quarter And Transitional Fiscal Year 2026 Financial Results And Provides Business Update
AnaptysBio Q2 collaboration revenue rises on higher Jemperli royalties
U.S. RESEARCH ROUNDUP-Masco, Sherwin-Williams, Vulcan Materials
U.S. RESEARCH ROUNDUP- Applied Materials, NVIDIA, Thermo Fisher Scientific
AnaptysBio's Q1 collaboration revenue falls, net loss widens
Brief: AnaptysBio Q1 Net Income USD -52.884 Million
Brief: Anaptys Appoints Chris Murphy As Chief Financial Officer And Owen Hughes To Board Of Directors
Brief: GSK Says Unit Tesaro's Claim For Declaratory Judgment Against Anaptysbio Unchanged
NASDAQ RESUMED AT 11:34 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:34 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:26 AM
U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks
U.S. STOCKS ON THE MOVE-Entergy, US natgas stocks, Brown-Forman, Datacentrex
U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
AnaptysBio falls after board approves First Tracks Biotherapeutics spinoff
Brief: Anaptys Announces $100 Million Stock Repurchase Plan And Provides A Business Update
Brief: First Tracks Biotherapeutics, The Planned Spin-Off Of Anaptys, Secures Commitments Of $145 Million In Private Placement